Skip to main
  1. Stocks
  2. Engene Holdings Inc
  3. Forecast
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is viewed favorably because detalimogene has a credible regulatory and commercial path in high-risk BCG-unresponsive NMIBC, supported by management’s confidence in accelerated approval and initial payer feedback that coverage is more likely if NCCN guidelines include the therapy. Its appeal is driven less by best-in-class efficacy than by practical advantages for community urology practices: simple administration, reduced workflow burden, and a tolerability profile with 91% of TRAEs Grade 1-2 and only 4.8% Grade 3 TRAEs. Although the pivotal dataset is still immature, AUA 2026 data showed a 54% CR anytime rate and 25% 12-month CR, while management believes ~$1B net sales could require about 10% share or ~2000 patients at parity pricing.

Bears say

enGene Therapeutics is facing a weaker fundamental setup because the pivotal LEGEND cohort has shown underwhelming durability, with the 12-month CR estimate at 25% after 32 newly assessed patients, and management has already reduced the workforce by about 50% and stopped enrollment in Cohorts 2a, 2b, and 3. The investment case now hinges on unproven assumptions that polidocanol can materially improve transfection and restore response consistency, yet the company still has no formal cash runway guidance despite reporting $285.2M of cash, cash equivalents, and marketable securities as of April 30, 2026. With clinical, regulatory, competitive, and financial risks all elevated, the stock looks vulnerable if the maturing data do not materially improve or if FDA and payer acceptance remains uncertain.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

ENGN Analyst Forecast & Price Prediction

Get the latest ENGN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ENGN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


ENGN Analyst Forecast & Price Prediction

Get the latest ENGN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ENGN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ENGN stock data and trends